Cromatina/Epigenética
Os inibidores de cromatina/epigenética são compostos que modulam a estrutura e função da cromatina ou interferem em modificações epigenéticas, como a metilação do DNA e a modificação de histonas. Esses inibidores são ferramentas essenciais para estudar a regulação da expressão gênica e o papel da epigenética em doenças como o câncer, distúrbios neurológicos e anomalias do desenvolvimento. Ao direcionar os processos epigenéticos, esses inibidores podem alterar os padrões de expressão gênica e oferecer novas vias terapêuticas. Na CymitQuimica, oferecemos uma ampla seleção de inibidores de cromatina/epigenética de alta qualidade para apoiar sua pesquisa em biologia molecular, genética e epigenética.
Subcategorias de "Cromatina/Epigenética"
Foram encontrados 2235 produtos de "Cromatina/Epigenética"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
KCL-440
CAS:<p>RS 57639 is a bioactive chemical.</p>Fórmula:C18H18N2O2Cor e Forma:SolidPeso molecular:294.35BPTF-IN-BZ1
<p>BPTF-IN-BZ1 is a BPTF inhibitor that possesses a high potency with a Kd of 6.3 nM.</p>Fórmula:C13H15ClN4OCor e Forma:SolidPeso molecular:278.74XY153
<p>XY153 (8l) is a BD2 selective BET inhibitor targeting BRD4, 3 & 2 with IC50s: 0.79, 5.31 & 5.09 nM, useful in acute myeloid leukemia & cancer research.</p>Fórmula:C33H34FN3O4Cor e Forma:SolidPeso molecular:555.64JAK2 JH2 binder-1
CAS:<p>JAK2 JH2 binder-1: potent, selective, Ki=37.1 nM, potential for studying myeloproliferative neoplasms.</p>Fórmula:C29H25N7O6SCor e Forma:SolidPeso molecular:599.62Azaphilone-9
CAS:<p>AZA-9 inhibits cancer growth by blocking HuR-ARE RNA binding; IC50=1.2μM.</p>Fórmula:C21H23BrO5Cor e Forma:SolidPeso molecular:435.3115:0 PG sodium
CAS:<p>15:0 PG sodium serves as an activator for the Protein Kinase C family and is an anionic phospholipid located in the membranes of mitochondria and microsomes. It plays a crucial role in the composition of pulmonary surfactants, especially within the membrane of the pulmonary lamellar bodies.</p>Fórmula:C36H70NaO10PCor e Forma:SolidPeso molecular:716.90PRMT5-IN-3
CAS:<p>PRMT5-IN-3 is a PRMT5 inhibitor.PRMT5-IN-3 is a combined DNA damaging agent that is synthetically lethal to tumor cells.</p>Fórmula:C22H23F3N4O3Cor e Forma:SolidPeso molecular:448.44GDC-9918
CAS:<p>GDC-9918 (compound GDC-9918) is an inhibitor of Janus kinases.</p>Fórmula:C20H18F2N6O5SCor e Forma:SolidPeso molecular:492.46P300-IN-4
<p>P300-IN-4 (compound 6) is a histone acetyltransferase p300 inhibitor with an IC50 value of 12.2 μM.</p>Fórmula:C29H28ClIN4O5Cor e Forma:SolidPeso molecular:674.91Tyk2-IN-20
CAS:<p>Tyk2-IN-20 (Example 289) is an effective inhibitor of Tyk2 with an IC50 value below 5 nM. Additionally, it inhibits JAK1, JAK2, and JAK3 with IC50 values under 100 nM. This compound is utilized for the research of inflammatory diseases.</p>Fórmula:C24H25N7O2Cor e Forma:SolidPeso molecular:443.50ROPA
CAS:<p>ROPA, a potent PKCalpha and PKCgamma activator, promotes tumor growth through PKC-activation.</p>Fórmula:C28H32O6Pureza:98%Cor e Forma:SolidPeso molecular:464.55CBP/p300-IN-18
<p>CBP/p300-IN-18 (compound 8) is a potent inhibitor of EP300/CBP HAT, acting on HAT EP300 (IC50: 0.056 μM) and LK2 H3K27 (IC50: 0.46 μM).</p>Fórmula:C25H27FN4O3Cor e Forma:SolidPeso molecular:450.51BET-IN-27
CAS:<p>BET-IN-27 (compound 6C) is an orally active BET inhibitor with IC50 values of 3.3 nM (BRD4-BD2), 3.4 nM (BRD4-BD1), 4.1 nM (BRD2-BD1), 20.4 nM (BRD3-BD1), and 42.0 nM (BRDT-BD1). It also exhibits antiproliferative activity.</p>Fórmula:C21H23N5O3SCor e Forma:SolidPeso molecular:425.5HDAC/Top-IN-1
CAS:<p>HDAC/Top-IN-1, an oral HDAC/Top inhibitor, targets HDAC1-3,6,8 with low IC50s; blocks S-phase & induces apoptosis in HEL cells.</p>Fórmula:C29H25FN4O4Cor e Forma:SolidPeso molecular:512.53JAK1-IN-16
<p>JAK1-IN-16 (compound 4l) acts as an inhibitor of JAK1/STAT3 and effectively downregulates the expression of TLR4 protein.</p>Fórmula:C20H15ClF3N3OSCor e Forma:SolidPeso molecular:437.87BBC0403
CAS:<p>BBC0403 is a BRD2 inhibitor, inhibiting BRD2 and BRD2, and suppresses NF-κB and MAPK signaling pathways.</p>Fórmula:C21H22N2O5Pureza:98.15%Cor e Forma:SolidPeso molecular:382.41JAK2-IN-11
CAS:<p>JAK2-IN-11 (Example 6) is a JAK2 kinase inhibitor with potent antitumor activity, exhibiting an IC50 of ≤10 nM against JH2 BIND WT/V617F. This compound effectively suppresses tumor growth.</p>Fórmula:C31H31F3N8O4Cor e Forma:SolidPeso molecular:639.64XP5
<p>XP5 is an oral HDAC6 inhibitor, potent against cancer cells, including YCC3/7 (IC50=31 nM to 2.31 μM).</p>Fórmula:C19H25N3O5SCor e Forma:SolidPeso molecular:407.48(R)-9b
CAS:<p>(R)-9b is an effective inhibitor of the ACK1 tyrosine kinase (IC50=56 nM) and exhibits anticancer activity. It selectively targets ACK1 but also inhibits kinases in the JAK family, specifically JAK2 and Tyk2. (R)-9b is used in research related to hormone-regulated cancers, such as prostate cancer and breast cancer.</p>Fórmula:C20H27ClN6OCor e Forma:SolidPeso molecular:402.92PARP1-IN-30
CAS:<p>PARP1-IN-30 is a specific and effective PARP1 inhibitor with cytotoxic properties. It precisely inhibits PARP1 in tumor cells lacking breast cancer 1 protein (BRCA1) or BRCA2. PARP1-IN-30 holds potential for use in cancer research.</p>Fórmula:C14H12ClNO4SCor e Forma:SolidPeso molecular:325.77KSQ-4279 (gentisate)
CAS:<p>KSQ-4279 (gentisate) (Compound Formula I) serves as an effective inhibitor of USP1 and a selective inhibitor of PARP1. This compound shows promise for use in cancer research.</p>Fórmula:C34H31F3N8O5Cor e Forma:SolidPeso molecular:688.66HIF-1/2α-IN-1
<p>HIF-1/2α-IN-1, an orally active compound, functions as an inhibitor of HIF-2α.</p>Fórmula:C17H16N6O4Cor e Forma:SolidPeso molecular:368.35(3S,4R)-Tofacitinib
CAS:<p>(3S,4R)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib is a JAK3 inhibitor(IC50 : 1 nM).</p>Fórmula:C16H20N6OPureza:98%Cor e Forma:SolidPeso molecular:312.37W4275
CAS:<p>W4275 (Compound 42) is a selective NSD2 inhibitor with oral activity and an IC50 of 17 nM. It exhibits antiproliferative activity, with an IC50 of 230 nM against RS411 cells, and significantly inhibits tumor growth in an RS411 tumor xenograft model. Pharmacokinetic analysis in mice shows that W4275 has a favorable oral bioavailability (F is 27.34%). W4275 holds potential for use in cancer research.</p>Fórmula:C25H36N6O3Cor e Forma:SolidPeso molecular:468.59GSK789
CAS:<p>GSK789 is a selective inhibitor of the first bromodomains (BD1) of the bromo and extra terminal domain (BET) proteins.</p>Fórmula:C26H33N5O3Cor e Forma:SolidPeso molecular:463.57PARP10/15-IN-1
<p>PARP10/15-IN-1 (compound 8l) is a dual PARP10 and PARP15 inhibitor with IC50s of 160 nM and 370 nM, respectively. It can be used in cancer research[1].</p>Fórmula:C13H10N2O3SCor e Forma:SolidPeso molecular:274.3PAD-IN-2
CAS:<p>PAD-IN-2, potent PAD4 inhibitor, IC50 <1 μM; targets autoimmune/cancer disorders.</p>Fórmula:C27H28ClN5O2Cor e Forma:SolidPeso molecular:490RK-582
CAS:<p>RK-582: oral spiroindolinone tankyrase inhibitor, halts colon cancer growth in COLO-320DM mouse model.</p>Fórmula:C27H35FN6O3Cor e Forma:SolidPeso molecular:510.6HDAC1-IN-8
CAS:<p>HDAC1-IN-8 (compound 5c) is a potent and selective HDAC1 inhibitor, with IC50 values of 11.94 µM for HDAC1, 22.95 µM for HDAC6, and greater than 500 µM for HDAC8. It exhibits antiproliferative activity, induces cell cycle arrest in G1 and G2/M phases, and triggers autophagy (autophagy). Additionally, HDAC1-IN-8 demonstrates anticancer properties and holds potential for lung cancer research.</p>Fórmula:C22H24N2O4Cor e Forma:SolidPeso molecular:380.437HDAC/HSP90-IN-4
<p>HDAC/HSP90-IN-4 inhibits HDAC (20 IC50=194nM, 26 IC50=360nM) & HSP90α (20 IC50=153nM, 26 IC50=77nM), affects cancer cell survival and invasion.</p>Fórmula:C20H23N3O6Cor e Forma:SolidPeso molecular:401.15869TDI-015051
CAS:<p>TDI-015051 is an orally active inhibitor of SARS-CoV-2 non-structural protein 14 (SARS-CoV-2 NSP14) with an IC50 of ≤0.15 nM. It effectively inhibits SARS-CoV-2 NSP14 in Huh-7.5 cells (EC50=11.4 nM) and A549 cells expressing ACE2-TMPRSS2 (EC50=64.7 nM). Additionally, TDI-015051 suppresses other coronaviruses such as α-hCoV-NL63, α-hCoV-229E, and β-hCoV-MERS with IC50 values of 1.7, 2.6, and 3.6 nM, respectively. This compound inhibits viral RNA methylation and replication by binding to a stable SAH-cap pocket and demonstrates anti-infection activity in mouse models.</p>Fórmula:C22H22FN5O4SCor e Forma:SolidPeso molecular:471.505(Rac)-RG108
CAS:<p>(Rac)-RG108 (NSC401077) is an inhibitor of DNMT1, effectively blocking DNA methyltransferases.</p>Fórmula:C19H14N2O4Cor e Forma:SolidPeso molecular:334.326JAK3 covalent inhibitor-1
CAS:<p>JAK3 Covalent Inhibitor-1 is a compound characterized by its potent and selective inhibition of Janus kinase 3 (JAK3), possessing an IC50 of 11 nM and</p>Fórmula:C22H17FN6O2SPureza:98%Cor e Forma:SolidPeso molecular:448.47AZ0108
CAS:<p>AZ0108, an oral PARP1,2,6 inhibitor, selectively blocks centrosome clustering, is viable for in vivo studies, and doesn't inhibit PARP3/TNKS1.</p>Fórmula:C24H20F4N6O2Cor e Forma:SolidPeso molecular:500.45Dot1L-IN-1
CAS:<p>The Ki value of DOT1L-in-1 is 2pm.It is a highly effective, selective and novel Dot1L inhibitor.</p>Fórmula:C32H36ClN9O2SPureza:98%Cor e Forma:SolidPeso molecular:646.21PARP14 inhibitor 1
CAS:<p>PARP14 inhibitor1 (compound Q22) is a selective inhibitor of PARP14 with an IC50 of 5.52 nM. It also exhibits anti-inflammatory properties and has a half-life of 182 minutes in mouse liver microsomes. This compound is applicable for atopic dermatitis research.</p>Fórmula:C23H27FN4O3Cor e Forma:SolidPeso molecular:426.484LSD1/2-IN-3
<p>LSD1/2-IN-3 selectively inhibits LSD1 (Ki 11 nM) over LSD2 (Ki 7 μM), and hinders tumor stem cell proliferation.</p>Fórmula:C9H8BrF2NCor e Forma:SolidPeso molecular:248.07G-631
CAS:<p>G-631 acts as a selective tankyrase inhibitor, effectively hindering tankyrase auto-PARsylation (poly ADP ribosylation) at an IC 50 of 7 nM and suppressing the Wnt signaling pathway. This compound also demonstrates favorable pharmacokinetic properties in mice.</p>Fórmula:C19H22F2N6O3Cor e Forma:SolidPeso molecular:420.41AJI-214
CAS:<p>AJI-214 functions as a dual-target inhibitor that specifically blocks Aurora kinase A and JAK2. By directly inhibiting Aurora kinase A, AJI-214 prevents mitotic progression and cell polarity in T cells while concurrently suppressing JAK2 activation to reduce STAT3 phosphorylation. This inhibition decreases the differentiation of TH1 and TH17 cells. AJI-214 is utilized in research focused on the modulation of immune responses and the prevention of graft-versus-host disease (GVHD).</p>Fórmula:C17H13ClFN5OCor e Forma:SolidPeso molecular:357.77AZ13824374
<p>AZ13824374: potent, selective ATAD2 inhibitor; anti-proliferative in breast cancer; pIC50: FRET 8.2, NanoBRET 6.2.</p>Fórmula:C30H39FN8O2Cor e Forma:SolidPeso molecular:562.68LSD1-IN-13 hydrochloride
CAS:<p>LSD1-IN-13 hydrochloride (7e) is an oral LSD1 inhibitor (IC50: 24.43 nM), promoting differentiation in AML cell lines.</p>Fórmula:C23H30ClN3O2SCor e Forma:SolidPeso molecular:448.02LSD1-IN-35
CAS:<p>LSD1-IN-35 (Compound Z-1) is a selective inhibitor of LSD1, exhibiting an IC50 of 108 nM. This compound inhibits the demethylation of H3K4me1/2 and acts as an immunomodulator. Additionally, LSD1-IN-35 enhances the responsiveness of gastric cancer cells to T-cell killing by reducing PD-L1 expression, thereby weakening the PD-1/PD-L1 interaction.</p>Fórmula:C25H26N4O2SCor e Forma:SolidPeso molecular:446.57SMARCA2/4-ligand-5
CAS:<p>SMARCA2/4-ligand-5 is the target protein ligand of PROTAC SMARCA2/4 degrader-37 (Example 4). PROTAC SMARCA2/4 degrader-37 (Example 4) is a PROTAC degrader of SMARCA2/4, with an IC50 value of ≤0.1 μM.</p>Fórmula:C20H13ClN4O3Cor e Forma:SolidPeso molecular:392.795PARP1-IN-29
CAS:<p>PARP1-IN-29 is an orally active PARP-1 inhibitor with an IC50 of 6.3 nM. When labeled with [18F], PARP1-IN-29 can be utilized for positron emission tomography (PET) imaging, specifically targeting PARP-1 in tumors. This compound is useful in oncology and imaging studies, particularly for detecting PARP-1 activity in cancer.</p>Fórmula:C18H16FN3O2Cor e Forma:SolidPeso molecular:325.34LSD1-IN-17
<p>LSD1-IN-17, a potent LSD1/CoREST/MAO inhibitor, IC50: 0.005/0.028/0.820 μM; hinders LNCaP prostate cancer cell growth, IC50: 17.2 μM.</p>Fórmula:C20H18N2OSCor e Forma:SolidPeso molecular:334.43TY-011
CAS:<p>TY-011 is an inhibitor of Aurora A/B kinases. This compound induces DNA damage and cell apoptosis (Apoptosis) in human gastric cancer cells by promoting abnormal microtubule-kinetochore attachments, effectively suppressing cancer cell proliferation. The IC50 values for TY-011 in human gastric cancer cell lines range from 0.11-4.49 μM. It is utilized in research focused on gastric cancer.</p>Fórmula:C18H16ClN5Cor e Forma:SolidPeso molecular:337.81PRMT5-IN-21
<p>PRMT5-IN-21 (compound 1) is a potent inhibitor of cyclonucleoside PRMT5.</p>Fórmula:C18H18F2N6O3Cor e Forma:SolidPeso molecular:404.37Menin-MLL inhibitor 4
CAS:<p>Menin-MLL inhibitor 4 has antitumor activity.Menin-MLL inhibitor 4 is an inhibitor of Menin- MLL (mixed-lineage leukemia protein) interaction .</p>Fórmula:C32H38FN7O3Pureza:98%Cor e Forma:SolidPeso molecular:587.69KAT6A-IN-2
CAS:<p>KAT6A-IN-2 (compound 7) is an inhibitor of KAT6A.</p>Fórmula:C23H29N5O5SCor e Forma:SolidPeso molecular:487.57AMI-408
CAS:<p>AMI-408 is a PRMT1 inhibitor that effectively reduces the levels of H4R3me2as in MLL-GAS7 leukemia cells.</p>Fórmula:C20H13Cl2N6NaO5SCor e Forma:SolidPeso molecular:543.32
